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Abstract 
 
Acute Respiratory Distress Syndrome (ARDS) is a very severe syndrome leading to 
respiratory failure and subsequent mortality. Sepsis is one of the leading causes of 
ARDS. Thus, extracellular bacteria play an important role in the pathophysiology of 
ARDS. Overactivated neutrophils are the major effector cells in ARDS. Thus, 
extracellular bacteria triggered TH17-like innate immunity with neutrophil activation 
might accounts for the etiology of ARDS. Here, microarray analysis was employed to 
describe TH17-like innate immunity-related cytokine including TGF-β and IL-6 
up-regulation in whole blood of ARDS patients. It was found that the innate 
TH17-related TLR1,2,4,5,8, HSP70, G-CSF, GM-CSF, complements, defensin, PMN 
chemokines, cathepsins, Fc receptors, NCFs, FOS, JunB, CEBPs, NFkB, and leukotriene 
B4 are all up-regulated. TGF-β secreting Treg cells play important roles in lung fibrosis. 
Up-regulation of Treg associated STAT5B and TGF-β with down-regulation of MHC 
genes, TCR genes, and co-stimulation molecule CD86 are noted. Key TH17 
transcription factors, STAT3 and RORα, are down-regulated. Thus, the full adaptive 
TH17 helper CD4 T cells may not be successfully triggered. Many fibrosis promoting 
genes are also up-regulated including MMP8, MMP9, FGF13, TIMP1, TIMP2, PLOD1, 
P4HB, P4HA1, PDGFC, HMMR, HS2ST1, CHSY1, and CSGALNACT. Failure to induce 
successful adaptive immunity could also attribute to ARDS pathogenesis. Thus, ARDS 
is actually a TH17-like and Treg immune disorder.  
  
 
Introduction 
 
Acute respiratory distress syndrome (ARDS) is a severe cause of respiratory failure. 
Despite of current treatment, the mortality rate remains very high. We still don’t 
have successful management strategies to deal with ARDS. Most important of all, we 
still don’t know the exact pathophysiology of ARDS. Sepsis or bacteremia is the 
leading cause of ARDS. Besides, neutrophil activation is reported in many studies in 
the lungs of ARDS patients. It was hypothesized that extracellular bacteria-induced 
TH17 immunity overactivation might be the etiology of ARDS. Microarray analysis to 
will be used to study the immune-related gene profiles in peripheral leukocytes of 
ARDS patients.  
 
According to Harrison’s internal medicine, the time course of ARDS can be divided 
into three stages.(1) First, the exudative phase. In this phase, injured alveolar 
capillary endothelium and type I pneumocytes cause the loss of tight alveolar barrier. 
Thus, edema fluid rich in protein accumulate in the interstitial alveolar spaces. It has 
been reported that cytokines (IL-1, IL-6, and TNF-α) and chemokines (IL-8, and 
leukotriene B4) are present in lung in this phase (2, 3). A great numbers of 
neutrophils traffic into the pulmonary interstitium and alveoli.(4, 5) Alveolar edema 
predominantly leads to diminished aeration and atelectasis. Hyaline membranes 
start to develop. Then, intrapulmonary shunting and hypoxemia develop. The 
situation is even worse with microvascular occlusion which leads to increasing dead 
space and pulmonary hypertension. The exudative phase encompasses the first 
seven days of disease after exposure to a precipitating ARDS risk factor such as sepsis, 
aspiration pneumonia, bacterial pneumonia, pulmonary contusion, near drowning, 
toxic inhalation injury, severe trauma, burns, multiple transfusions, drug overdose, 
pancreatitis, and post-cardiopulmonary bypass.  
 
Second, proliferative phase. This phase usually lasts from day 7 to day 21. Although 
many patients could recover during this stage, some patients develop progressive 
lung injury and early change of pulmonary fibrosis. Histologically, this phase is the 
initiation of lung repair, organization of alveolar exudates, and a shift from a 
neutrophil to a lymphocyte dominant pulmonary infiltrate. There is a proliferation of 
type II pneumocytes which can synthesize new pulmonary surfactants. They can also 
differentiate into type I pneumocytes. In addition, there is beginning of type III 
procollagen peptide presence which is the marker of pulmonary fibrosis. 
 
Third, fibrotic phase. Although many patients with ARDS recover lung function three 
weeks after the initial lung injury, some enter a fibrotic phase that may require long 
term support on mechanical ventilators. Histologically, the alveolar edema and 
inflammatory exudates in early phases are converted to extensive alveolar duct and 
interstitial fibrosis. Intimal fibroproliferation in the pulmonary microvascular system 
leads to progressive vascular occlusion and pulmonary hypertension.   
 
Material and Methods 
 
Microarray dataset 
 
According to Dr. J. A. Howrylak’s research in Physiol Genomics 2009, who collected 
total RNA from whole blood in sepsis and sepsis-induced ARDS patients.(6) He tried 
to find out molecular signature of ARDS compared to sepsis patients. His dataset is 
available in Gene Expression Omnibus (GEO) www.ncbi.nlm.nih.gov/geo (accession 
number GSE 10474). The total number of his sepsis-induced ARDS is 13. The overall 
mortality of these patients is 38%. The second dataset is from GSE20189 of Gene 
Expression Omnibus. This dataset was collected by Dr. Melissa Rotunno in Cancer 
Prevention Research 2011.(7) Molecular signature of early stage of lung 
adenocarcinoma was studied by microarray. We use the healthy control (sample size 
21) whole blood RNA from this dataset to compare the ARDS patients. In this study, 
we perform further analysis to study peripheral leukocyte gene expression profiles of 
ARDS compared to those of healthy controls.  
 
Statistical analysis 
 
Affymetrix HG-U133A 2.0 genechip was used in both samples. RMA express software 
(UC Berkeley, Board Institute) was used to do normalization and to rule out the 
outliners of the above dataset. The potential outliners of samples were removed 
according to the following criteria:  
1. samples which have strong deviation in NUSE plot 
2. samples which have broad spectrum in RLE value plot 
3. samples which have strong deviation in RLE-NUSE mutiplot 
4. samples which exceed 99% line in RLE-NUSE T2 plot. 
 
Then, Genespring XI software was done to analyze the significantly expressed genes 
between ARDS and healthy control leukocytes. P value cut-off point is set to be less 
than 0.05. Fold change cut-off point is >2.0 fold change. Benjamini-hochberg 
corrected false discovery rate was used during the analysis. Totally, a genelist of 3348 
genes was generated from the HGU133A2.0 chip with 18400 transcripts including 
14500 well-characterized human genes. 
 
RT-PCR confirmation 
 
Dr. J. A. Howrylak performed real time PCR for selected transcripts (cip1, kip2) by 
using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). In the 
second dataset, Dr. Melissa Rotunno also performed qRT-PCR test to validate the 
microarray results. RNA quantity and quality was determined by using RNA 600 
LabChip-Aligent 2100 Bioanalyzer. RNA purification was done by the reagents from 
Qiagen Inc. All real-time PCRs were conducted by using an ABI Prism 7000 Sequence 
Detection System with the designed primers and probes for target genes and an 
internal control gene-GAPDH. This confirms that their microarray results are 
convincing compared to RT-PCR results. 
 
Results 
 
RMA analysis of whole blood from healthy normal control 
 
The RMA analysis was performed for RNA samples from whole blood of healthy 
control of the lung adenocarcinoma dataset. Raw boxplot, NUSE plot, RLE value plot, 
RLE-NUSE multiplot, and RLE-NUSE T2 plot were generated. Then, sample was 
included and excluded by using these graphs (Figure 1A, 1B, 1C, 1D, 1E). Because of 
the strong deviation in the T2 plot, the sample GSM506435 was removed for the 
further analysis.  
 
RMA analysis of whole blood from acute lung injury patients 
 
The RMA analysis was performed for RNA samples from whole blood of healthy 
control of the ARDS dataset. Raw boxplot, NUSE plot, RLE value plot, RLE-NUSE 
multiplot, and RLE-NUSE T2 plot were generated. Then, sample was included and 
excluded by using these graphs (Figure 2A, 2B, 2C, 2D, 2E) 
 
TH17-like innate immunity and Treg-related genes are up-regulated in ARDS 
 Based on the microarray analysis, we found out that many TH17-related genes are 
up-regulated in ARDS including Toll-like receptors 1,2,4,5,8, complement, heat shock 
protein 70, cathpesin, S100A proteins, leukotrienes, defensins, TH17-related 
chemokines, and MMPs. Many fibrosis related genes are also up-regulated including 
key collagen synthesis enzymes and fibroblast growth factor. Key TH17 initiating 
cytokines including TGF beta and IL-6 are also up-regulated. This explains that 
TH17-like immunity is initiated in ARDS. NK cell and T cell related genes are 
down-regulated. This explains that TH1 or THαβ immunological pathway is not 
triggered in ARDS. In addition, TGFB1 and STAT5B up-regulations suggest that Treg 
cells play important roles in ARDS pathogenesis. (Table 1-14) 
 
In Table 1, it can be seen that the TLR1, 2,4,5,8 were up-regulated with the 
expression of IRAK4. Thus, toll-like receptor signaling is generated during ARDS. It is 
worth noting that TLR1,2,4,5,8 are all anti-bacteria TH17 innate immunity signaling 
(TLR8 is against CpG rich oligonucleotides). Thus, strong TH17-like related Toll 
signaling can be activated. 
 
In Table 2, differentiated expression of heat shock proteins can be seen. Most 
important of all, HSPA1A, HSPA1B, and HSPA4 are up-regulated. HSPA1A and HSPA1B 
are greater than 6.0 fold up-regulation. These heat shock proteins are HSP70 family 
which can activate TH17 related toll-like receptors (TLR2 and TLR4) to generate 
anti-bacterial immunity. Because of the co-upregulation of TLR2/4 and HSP70, it is 
evident that the proinflammatory signaling is generated in acute lung injury. 
 
In Table 3, chemokine and chemokine receptor genes are differentially regulated. 
TH1 T cell chemotaxis factor CCL5 with its receptor CCR1 and CCL4 with its receptor 
CCR5 are both down-regulated. TH2 eosinophil chemotaxic factor receptor CCR3 and 
THαβ NK cell chemotaxic factors XCL1 and XCL2 are all down-regulated. However, 
TH17-related chemokines such as PAF related molecules and S100A binding proteins 
are up-regulated. These findings suggest that TH17-like related response to recruit 
neutrophils is initiated. Toll-like receptor signaling can activate these TH17-like 
chemokines.  
 
In Table 4, strikingly and surprisingly, all the MHC related genes are down-regulated 
during acute lung injury. These genes include HLA-DRB, HLA-DRA, HLA-DQB, HLA-DPA, 
HLA-DQA, and HLA-DMB. The HLA-DQA1 has the lowest expression level with greater 
than 5.8 fold down-regulation. Thus, MHC antigen presentation genes are 
down-regulated in acute lung injury. 
 
In Table 5, many immune-related transcription factors are up-regulated or 
down-regulated. Key Treg related key transcription factor, STAT5B, is up-regulated(8). 
And, THαβ and TH1 related key transcription factor, STAT1, is down-regulated. In 
addition, TH2 related transcription factor, GATA3, is also down-regulated. Surprisingly, 
key TH17 transcription factors, STAT3 and RORα, are down-regulated.(9) These 
findings suggest that full TH17 immunity may not be activated during ARDS. Other 
innate immunity related genes for myeloid or granulocyte lineages are up-regulated 
including AP1 (Fos and Jun), CEBP family genes, and NFIL3. It is worth noting that the 
inhibitor of NFkB, key innate immunity mediator, is down-regulated in acute lung 
injury. Besides, T cell related transcription factors including NFATC3, NFAT5, and 
NFATC2IP are down-regulated in ARDS. JAK2, a signal transduction for all cytokines 
and STATs proteins, is also up-regulated. STAT5B is the key transcription factor for 
regulatory T cells. And, down-regulation of RORα and STAT3 means only TH17-like 
innate immunity is activated in acute lung injury. 
 
In Table 6, it can be seen that many chemotaxic factors, leukotrienes and 
prostaglandins, are up-regulated or down-regulated. The key enzyme: leukotriene A4 
hydrolase for leukotriene B4, a potent PMN chemoattractant, is up-regulated. 
Besides, leukotriene B4 receptor is also up-regulated. Furthermore, the receptor of 
PGD2, a TH2 related effector molecule, is 9 fold down-regulated. In addition, the 
gene 15-hydroxyprostaglandin dehydrogenase (HPGD), which is responsible for 
shutting down prostaglandin, is 27 fold up-regulated. Key molecules including 
phospholipase A 2 and arachidonate 5-lipoxygenase to initiate leukotriene synthesis 
are also up-regulated in ARDS. And, formyl peptide receptor 2, another chemotaxic 
receptor of PMN, is also up-regulated. Innate immune initiators, SERPINB1 and 
SERPINB2, are also up-regulated in acute lung injury. 
 
In Table 7, many fibrosis related genes are up-regulated during ARDS. Most strikingly, 
Matrix metalloproteinase 8 (MMP8) has greater than 28 fold up-regulation. Matrix 
metalloproteinase 9 (MMP9) has greater than 11 fold up-regulation. MMP8 & MMP9 
play key roles in the pathogenesis of ARDS(10). In addition, MMP25, TIMP1, and 
TIMP2 are also up-regulated in ARDS. Thus, severe extracellular matrix destruction 
happens in ARDS. Fibroblast growth factors including FGF13 (5 fold up-regulation) 
and PDGFc (12 fold up-regulation) are also significantly expressed. Chondroitin 
sulfate deposition is reported in pulmonary fibrosis (11). In this study, chondroitin 
sulfate synthetase and chondroitin sulfate N-acetylgalactosaminyltransferase 1 & 2 
are also found up-regulated. There is 7.5 fold up-regulation in chondroitin sulfate 
N-acetylgalactosaminyltransferase 1 and 13 fold up-regulation in chondroitin sulfate 
N-acetylgalactosaminyltransferase 2. Carboxypeptidase D, which can up-regulate 
nitric oxide, is also up-regulated in acute lung injury.(12) Previous studies also found 
up-regulation of iNOS as well as nitric oxide during the inflammation in ARDS.(13) 
Heparanse and heparan sulfate 2-O-sulfotransferase 1 are also up-regulated in ARDS. 
Heparan sulfate sulfation is a potent stimulation of FGF signaling to cause fibrosis (14, 
15). Hyaluronan-mediated motility receptor (RHAMM) is also up-regulated. 
Hyaluronan plays an important role in pulmonary fibrosis. In addition, key collagen 
synthesis enzymes, prolyl-4-hydroxylases and procollagen-lysine 1, 2-oxoglutarate 
5-dioxygenase are also up-regulated in ARDS.(16, 17) 
 
In Table 8, many complement related genes are up-regulated including CD59, C1QB, 
ITGAM, CR1, C3AR1, ITGAX, C1QA, C1RL, and C5AR1. Complements are important in 
the TH17 arm to kill extracellular bacteria. Thus, the whole complement machinery is 
activated in ARDS. In addition, two defensin genes, DEFA1B3 and DEFA4, are also 
up-regulated to defend the possible bacterial infection. Neutrophil overactivity with 
up-regulated complements and defensins plays a vital role in acute lung injury. 
 
In Table 9, many cathepsin genes are up-regulated in acute respiratory distress 
syndrome including CTSK, CTSG, CTSZ, CTSA, CTSD, and CTSC except CTSO and CTSW. 
Cathepsins are important proteases in antigen processing. Thus, antigen processing 
is likely to be activated in ARDS. However, MHC related genes are down-regulated in 
acute lung injury. In addition, myeloperoxidase, which is the enzyme responsible for 
ingested bacteria killing, is upregulated in ARDS. Neutrophil cytosolic factor 1 & 4, 
the subunit of NADPH oxidase for ingested bacteria killing, are also up-regulated in 
ARDS. 
 
In Table 10, two CSF receptors are up-regulated in acute lung injury. CSF2 receptor 
(GM-CSF receptor) is more than two fold up-regulated. And, CSF3 receptor (G-CSF 
receptor) is also more than two fold up-regulated. GM-CSF and G-CSF can stimulate 
granulocyte and monocyte proliferation. It means that myeloid and granulocyte 
lineages are proliferative in ARDS.   
 
In Table 11, Fc receptor related genes including IgG Fc receptor 2A, IgA Fc receptor, 
IgG Fc receptor 2C, IgG Fc receptor 1B, and IgG Fc receptor 1A/1C are up-regulated in 
ARDS. These Fc receptors (CD32 & CD64), expressed on myeloid lineages, are related 
to TH17-related immunological pathway. Besides, TH2 related IgE Fc receptor 1A is 
down-regulated. These findings support that TH17-like armed innate immune 
response is activated in acute lung injury. 
 
In Table 12, many TH17-like related cytokine genes are up-regulated in ARDS. Most 
importantly, the central TH17 cytokine initiators, TGFB1 and IL-6, are up-regulated in 
ARDS. Thrombospondin (THBS1), the activator of TGFB, is also strongly up-regulated. 
In addition, TH22 related cytokines such as IL32 and IL1A are down-regulated. And, 
IL1RN, an IL1 antagonist, is up-regulated. The receptors of TH17 immunity are also 
down-regulated, including IL17RA, IL6R, and TGFBR3. The receptors for Treg pathway 
are also down-regulated, including IL2RB and TGFBR3. However, the key TH17 
downstream IL-6/TGFβ inducing transcription factors, STAT3 and RORα, are 
down-regulated. These findings suggest that only TH17-like innate immunity is 
up-regulated. Other immunological pathway cytokine receptors are up-regulated, 
including IL1RA, IL1R2, IL1R1, IL4R, IL18R1, IFNGR1, IFNGR2, IFNAR1, and TNFRSF1A. 
Besides, TH1 or THαβ associated interferon related genes are down-regulated, 
including ISG20L2, IFI16, GVINP1, GBP1, IFI44L, and IFIT3. In addition, FAS is 
up-regulated and Fas apoptotic inhibitory molecule 3 (FAIM3) is down-regulated. 
These findings suggest that apoptosis machinery is activated in ARDS.  
  
In Table 13, many important CD molecules are differentially regulated. CD molecules 
are important in mediating host immune reaction. Thus, the up-regulation or 
down-regulation of these CD molecules suggests the status of host immunity. From 
this table, we can see that many T cell activation molecules are down-regulated, 
including CD8A, CD3G, CD3D, and CD86. CD8A is the molecule of cytotoxic T cell 
activation. CD3G is the molecule for helper or killer T cell activation. CD86 is the key 
co-stimulation signal to activate B cells and T cells. Thus, the adoptive immunity 
including B and T lymphocytes are not likely to be activated in ARDS.  
 
In the Table 14, many NK cells and T cell related molecules are seen to be 
down-regulated. Molecules related to NK cell activation include grazymes (GZMK, 
GZMM, GZMB, and GZMH), perforin(PRF1), and killer cell receptors (KLRK1, KLRD1, 
KLRG1, KLRB1, NKTR, and KLRF1). NKTR is 13-fold down-regulated and granulysin 
(GNLY) is 5-fold down-regulated. NK cells are the key effector cells in THαβ immunity. 
Thus, THαβ immunity is not activated or even down-regulated in ARDS. In addition, 
many TCR related genes are also down-regulated, including TRBC1, TRAC/J17/V20, 
TRBC2, TRD@, TRAP/TRGC2, and TRDV3. Several TCR related genes have greater than 
5-fold down-regulation. We can see the down-regulations of MHC genes, CD 
costimulation molecules, STAT3, and TCR genes as well as the up-regulation of TGFB1 
and STAT5B. These findings suggest that T cells are not activated in the acute lung 
injury. Thus, adaptive immunity cannot be successfully triggered in ARDS. Because 
successful adaptive TH17 helper cells need at least three signals: TGFβ, IL-6, and TCR. 
The absence of TCR signal cannot fully trigger TH17 CD4 T cells. Our findings suggest 
that Treg plays an important role in ARDS pathophysiology. 
 
Discussion 
ARDS is a very severe respiratory complication. Sepsis is the major risk factor of ARDS. 
Sepsis is caused by the uncontrolled bacteremia due to bacterial infection. In 
addition, PMNs overactivation is very important in the pathogenesis of ARDS. Thus, 
extracellular bacteria induced TH17 immunity with neutrophil activation might be 
the key in the pathophysiology of ARDS.  
 
Here, I propose a detail pathogenesis to explain the three stages of ARDS. In the first 
exudative stage, neutrophils are attracted to lung due to chemotaxic agents such as 
IL-8 or C5 or leukotriene B4. During sepsis, bacterial infection in pulmonary tissue can 
trigger pulmonary epithelial cells, pulmonary endothelial cells, pulmonary fibroblast, 
and alveolar macrophage to be activated. Toll-like receptors 1,2,4,5 as well as heat 
shock proteins (HSP60, HSP70) are key molecules to trigger TH17 host immunity 
(18-26). Heat shock proteins are important stress proteins in situation such as burn, 
trauma, hemorrhagic shock, near drowning or acute pancreatitis.(27-29) HSP60 and 
HSP70 can activate TH-17 related Toll-like receptors. Thus, TH17 related cytokines 
such as IL-17, IL-1, TNF-α, and IL-6 as well as TH-17 related chemokines such as IL-8 
and other CXCL group chemokines will be triggered. Bacterial infection can let 
pulmonary epithelial cells to release chemokines and cytokines.(30-32) TH17 
cytokines will start to activate TH17 immunity including activating PMN effector 
function for immunity against extracellular bacteria. The cytokine storm during ARDS 
is now explained. However, in this study, it was found that CD86 costimulation signal, 
TCR genes, and majority of MHC genes are down-regulated in ARDS. Thus, adaptive 
full TH17 immunity related effective and specific antibody and TCR response against 
bacteria may not be triggered. However, one research found that there is IL-8 
autoantibody in ARDS patients.(33) IL-8 as well as leukotriene B4 is the main 
chemoattractant in pulmonary tissue.(34-40) It was first identified in lung giant cell 
lines.(41) Besides, IL-8 has high affinity to bind to the heparin sulfate and chondroitin 
sulfate-enriched lung tissue.(42, 43) And, IL-8 retention in pulmonary tissue can 
further recruit neutrophils to lung. This can explain why IL-8 secreted from distant 
site such as pancreas during acute pancreatitis can cause ARDS. However, IL-8 itself is 
not changed in this study. And, there are several limitations in the IL8 autoantibody 
study (33). First, anti-IL8-IL8 complex can be detected in 55% of healthy control 
serum. There is no significant difference of IL8-antiI-L8 complex between ARDS 
patients’ serum and healthy controls’ serum. In addition, IL8 autoantibody can 
suppress IL8 binding activity for neutrophils and it can reduce IL8’s chemotaxic 
activity. Thus, IL8 autoantibody’s importance in ARDS pathogenesis is doubtful. 
Besides, several studies can support the role of TH17 immunity in the pathogenesis 
of ARDS. G-CSF, the growth factor of neutrophils, can cause the common symptoms 
of ARDS.(44) And, suppression of NFkB can attenuate ARDS progression.(45, 46) Key 
THαβ cytokine, IL-10, can reduce the severity of ARDS.(47)  
 
Bacterial infection is the most common risk factor of ARDS. However, certain 
pathogens other than bacteria also are risks for developing ARDS. Plasmodium 
falciparum malarial infection can also cause the complication of ARDS. The reason for 
this is that Plasmodium falciparum can activate heat shock proteins to trigger TH17 
immunity to cause ARDS.(author’s paper in press)(48) SARS-CoV and H1N1 Avian flu 
virus can also down-regulate normal anti-viral interferon-α/β and up-regulate 
TH17-like immunity to trigger ARDS. (author’s paper in press: Viral Immunology)(49, 
50) Thus, the above phenomena suggest that TH17 inflammation is the key to the 
pathogenesis of ARDS. If different pathogens lead to a common pathway of 
TH17-related innate immunity, they will cause the same consequence of ARDS. It is 
also seen in burn, trauma, or pancreatitis when TH17-like innate immunity is also 
activated.  
 
In the second proliferative stage, lymphocytes replace neutrophils and become the 
dominant population in ARDS. These lymphocytes are TH17-like lymphocytes and 
Treg lymphocytes. TH17-related cytokines such as IL-17, IL-1, IL-6, and TNF-α can 
continue the inflammatory process due to the activation of innate immunity. 
However, once the bacterial antigen during sepsis is cleared, Toll-like receptor 
signaling is stopped, and no further proinflammatory cytokines such as IL-6 are 
synthesized. In addition, there is no TCR signal found in this study. Thus, TH17 
adaptive immunity may not be successfully generated. This could be very important 
in ARDS pathogenesis. In TH17 immunity, both TGF-β and IL-6 are two important 
triggering cytokines. If there is no longer IL-6 signaling, only TGF-β is generated. IL-6 
is the key factor to regulate the balance between Treg cells and TH17 cells. If there is 
enough IL-6, Treg cells will become TH17 cells. If there is not enough IL-6, TGF-β 
secreting Treg cells will be maintained. Treg cells are associated with STAT5B 
activation. Thus, in the third fibrosis stage, TGF-β secreting Treg cells are the 
dominant effector cells in ARDS.(51) In this study, patients’ ARDS is induced by 
bacterial sepsis. Thus, failure to induce specific adaptive immunity such as TCR and 
antibody cannot successfully defeat these bacteria. In the early disease stage, 
overactive innate immunity with PMN activation causes severe lung consolidation. In 
the later stage, failure of adaptive immunity against bacteria causes the abundant 
regulatory T cells secreting TGF-β. TGF-β is a very strong fibrosis promoting agent and 
is the most important and potent stimulant in tissue fibrosis.(52, 53) TGF-β will 
promote the synthesis of multiple collagen genes.(54) Thus, overproduction of TGF-β 
in lung tissue will cause pulmonary fibrosis. TGF-β caused fibrosis is usually a process 
for repairing cavity after bacterial infection locus such as abscess. This mechanism 
can solve many controversial studies before. Several studies found that TLR4 and 
heat shock proteins can aggravate ARDS.(20) However, another studies found that 
TLR4 or heat shock protein can protect from pulmonary fibrosis after acute lung 
injury.(55-57) It is because TLR and heat shock signaling can maintain the activation 
of proinflammatory cytokines such as IL-6. Thus, no sole TGF-β overproduction 
happens in lung fibrosis. In an animal study, neutrophil inhibitor can attenuate the 
progression of acute lung injury (58). Thus, TH17 and Treg inflammatory process can 
fully explain the pathogenesis of ARDS. 
 
Recently, two researches suggested that Treg cells play protective roles in acute lung 
injury.(59, 60) We cannot agree with their suggestions. First of all, they used Rag-/- 
mice and found that ARDS is reduced in Rag-/- mice. However, both B cells and T cells 
are absent in Rag-/- mice. This finding can be explained that adaptive immune T & B 
lymphocytes relieve the TH17 innate ARDS pathological change. They also found that 
CD8 T cells have protective roles in ARDS. In this study, we found that antigen specific 
T cells are not activated in ARDS. Thus, specific TCR or antibody response against 
bacteria antigen could not be successfully triggered in acute lung injury. If the 
adaptive immunity can be triggered, it can limit ARDS pathogenesis. Second, they 
used a lung injury scoring system to assess the severity of ARDS. However, the 
scoring system only included lung congestion and inflammatory infiltration. The most 
important sequel of ARDS, pulmonary fibrosis, was not included in their studies. Thus, 
their conclusion that TGF beta secreting Treg cells can protect ARDS is questionable . 
Actually, anti-TGFB antibody can prevent mice from lung fibrosis.(61) After knowing 
the complete pathophysiology ofARDS, we may be able to develop better treatment 
strategies to managing this highly detrimental and fatal disease. 
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Figure legends 
 
Figure 1. RMA express plot for selecting samples in healthy controls. 
1-A NUSE boxplot for normal control 
1-B RLE boxplot for normal control 
1-C RLE-NUSE multiplot for normal control 
1-D RLE-NUSE T2 plot for normal control 
1-E Raw data Boxpolt for normal control 
 
Figure 2. RMA express plot for selecting samples in ARDS patients. 
2-A NUSE boxplot for ARDS patients 
2-B RLE boxplot for ARDS patients 
2-C RLE-NUSE multiplot for ARDS patients 
2-D RLE-NUSE T2 plot for ARDS patients 
2-E Raw data Boxplot for ARDS patients 
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Table 1. Toll-like receptor 
   Probe Set ID P value Arrow Fold Gene Symbol 
204924_at 6.89E-09 up 3.412607 TLR2 
210166_at 1.85E-07 up 2.732714 TLR5 
210176_at 3.49E-04 up 2.256822 TLR1 
220832_at 1.23E-07 up 5.041227 TLR8 
221060_s_at 8.48E-06 up 2.713024 TLR4 
219618_at 1.79E-09 up 3.059633 IRAK4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Heat Shock Protein 
  Probe Set ID Pvalue Arrow Fold Gene Symbol 
200598_s_at 5.09E-07 down 2.56764 HSP90B1 
200800_s_at 8.10E-08 up 3.152098 HSPA1A /// HSPA1B 
202557_at 2.10E-04 up 2.438485 HSPA13 
202581_at 1.79E-11 up 6.14778 HSPA1A /// HSPA1B 
208744_x_at 1.45E-08 down 2.109862 HSPH1 
208815_x_at 6.07E-07 up 2.042983 HSPA4 
210338_s_at 4.69E-08 down 2.607109 HSPA8 
211969_at 9.22E-14 down 15.02711 HSP90AA1 
219284_at 4.74E-04 up 2.277097 HSPBAP1 
200941_at 7.08E-09 up 2.341059 HSBP1 
200942_s_at 1.40E-05 up 2.092604 HSBP1 
208810_at 9.82E-04 up 2.226605 DNAJB6 /// TMEM135 
209015_s_at 2.14E-07 up 2.790782 DNAJB6 
209157_at 9.23E-10 up 3.232302 DNAJA2 
212467_at 6.04E-10 up 4.209722 DNAJC13 
212908_at 1.42E-10 down 3.075077 DNAJC16 
212911_at 3.41E-09 up 3.145019 DNAJC16 
202842_s_at 6.90E-04 up 2.138169 DNAJB9 
206782_s_at 6.78E-09 up 2.321206 DNAJC4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Table 3. Chemokine 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
1405_i_at 5.89E-04 down 2.63913 CCL5 
204103_at 8.18E-05 down 2.515743 CCL4 
204655_at 7.65E-04 down 2.245439 CCL5 
205099_s_at 1.52E-06 down 2.461891 CCR1 
205898_at 7.09E-06 down 4.04859 CX3CR1 
206337_at 1.20E-07 down 4.466033 CCR7 
206366_x_at 5.25E-11 down 5.07455 XCL1 
206991_s_at 1.51E-04 down 2.039673 CCR5 
208304_at 4.89E-06 down 4.671167 CCR3 
214567_s_at 1.62E-08 down 3.339736 XCL1 /// XCL2 
219161_s_at 4.46E-07 up 2.387246 CKLF 
221058_s_at 9.57E-08 up 2.487534 CKLF 
200660_at 9.31E-10 up 2.113736 S100A11 
200815_s_at 1.43E-11 up 2.871307 PAFAH1B1 
202917_s_at 3.16E-09 up 2.744783 S100A8 
203535_at 2.25E-13 up 2.882588 S100A9 
204351_at 4.60E-04 up 2.44348 S100P 
205863_at 7.00E-10 up 4.3815 S100A12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. MHC 
    Probe Set ID P value Arrow Fold Gene Symbol 
204670_x_at 9.95E-11 down 3.865348 HLA-DRB1/4 
208306_x_at 9.05E-09 down 2.986262 HLA-DRB1 
208894_at 3.15E-10 down 4.546559 HLA-DRA 
209312_x_at 4.77E-09 down 3.655453 HLA-DRB1/4/5 
209823_x_at 1.81E-04 down 2.484667 HLA-DQB1 
210982_s_at 8.58E-08 down 3.12086 HLA-DRA 
211656_x_at 4.91E-05 down 2.002577 HLA-DQB1  
211990_at 1.49E-06 down 3.785754 HLA-DPA1 
211991_s_at 1.37E-08 down 3.178668 HLA-DPA1 
212671_s_at 3.46E-04 down 2.569759 HLA-DQA1/2 
212998_x_at 2.28E-05 down 2.456309 HLA-DQB1  
213537_at 2.69E-05 down 2.602025 HLA-DPA1 
215193_x_at 1.62E-08 down 3.284869 HLA-DRB1/3/4 
217478_s_at 1.25E-07 down 2.783175 HLA-DMA 
221491_x_at 4.58E-06 down 2.600531 HLA-DRB1/3/4/5 
201137_s_at 1.25E-06 down 2.815927 HLA-DPB1 
203290_at 4.64E-08 down 5.873323 HLA-DQA1 
203932_at 7.50E-07 down 2.382645 HLA-DMB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Transcription factor 
  Probe Set ID P value Arrow Fold GeneSymbol 
205026_at 2.14E-10 up 2.427908 STAT5B 
208991_at 5.85E-09 down 3.745264 STAT3 
209969_s_at 1.14E-05 down 3.752185 STAT1 
212549_at 4.02E-11 up 2.520162 STAT5B 
212550_at 3.90E-09 up 2.643262 STAT5B 
209189_at 1.67E-04 up 2.499937 FOS 
218880_at 4.95E-08 up 3.472536 FOSL2 
201473_at 7.18E-08 up 2.59816 JUNB 
212501_at 7.61E-09 up 2.240303 CEBPB 
213006_at 1.41E-09 up 3.735119 CEBPD 
214523_at 2.02E-06 up 2.091157 CEBPE 
204039_at 1.40E-08 up 2.398913 CEBPA 
204203_at 1.31E-08 up 2.358698 CEBPG 
203574_at 1.13E-08 up 4.640286 NFIL3 
201502_s_at 5.83E-06 down 2.115988 NFKBIA 
205841_at 2.40E-13 up 5.992293 JAK2 
205842_s_at 2.73E-06 up 3.288805 JAK2 
209604_s_at 4.81E-16 down 6.909352 GATA3 
210555_s_at 1.03E-05 down 2.547481 NFATC3 
210556_at 5.20E-05 down 2.429433 NFATC3 
215092_s_at 1.12E-05 down 2.197351 NFAT5 
217526_at 3.36E-08 down 3.459827 NFATC2IP 
217527_s_at 1.86E-10 down 4.586211 NFATC2IP 
10426_x_at 8.86E-10 down 5.364871 RORA 
 210479_s_at 9.23E-10 down 6.440884 RORA 
  
 
 
 
 
 
 
 
 
 
 
Table 6. Leukotriene & prostaglandin 
 Probe Set ID P value Arrow Fold GeneSymbol 
208771_s_at 1.53E-08 up 2.726662 LTA4H 
210128_s_at 8.83E-10 up 3.067644 LTB4R 
216388_s_at 4.30E-09 up 2.518544 LTB4R 
215894_at 1.13E-11 down 9.422997 PTGDR 
203913_s_at 3.16E-10 up 27.23115 HPGD 
203914_x_at 3.10E-09 up 19.87965 HPGD 
204445_s_at 1.10E-06 up 2.227303 ALOX5 
204446_s_at 3.10E-08 up 2.322821 ALOX5 
204614_at 3.94E-06 up 2.905599 SERPINB2 
209533_s_at 1.09E-08 up 2.612623 PLAA 
210145_at 1.31E-09 up 3.562516 PLA2G4A 
210772_at 3.05E-08 up 4.401296 FPR2 
210773_s_at 3.42E-06 up 3.867929 FPR2 
213572_s_at 2.12E-12 up 6.133628 SERPINB1 
214366_s_at 4.55E-09 up 3.975351 ALOX5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table7. MMP and FGF 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
207329_at 1.17E-08 up 28.02386 MMP8 
207890_s_at 1.46E-09 up 3.310085 MMP25 
203936_s_at 2.84E-12 up 11.50853 MMP9 
205110_s_at 2.26E-06 up 5.236618 FGF13 
201666_at 1.46E-08 up 2.519345 TIMP1 
203167_at 2.47E-10 up 3.173297 TIMP2 
219295_s_at 7.61E-07 up 6.184153 PCOLCE2 
200827_at 2.27E-07 up 2.158958 PLOD1 
200654_at 1.47E-09 up 2.244832 P4HB 
201940_at 2.24E-08 up 5.123088 CPD 
201941_at 8.36E-08 up 4.763787 CPD 
201942_s_at 2.76E-06 up 3.149759 CPD 
201943_s_at 6.79E-10 up 6.419939 CPD 
202304_at 1.23E-09 up 3.617562 FNDC3A 
203044_at 1.34E-05 up 3.342165 CHSY1 
203284_s_at 2.64E-08 up 3.515453 HS2ST1 
203285_s_at 9.15E-10 up 2.626396 HS2ST1 
207165_at 7.94E-05 up 2.063695 HMMR 
207543_s_at 9.43E-07 up 2.718742 P4HA1 
211945_s_at 0.001738 up 2.065411 ITGB1 
218718_at 2.24E-10 up 12.04417 PDGFC 
219049_at 1.52E-08 up 7.475137 CSGALNACT1 
219403_s_at 1.33E-07 up 5.223431 HPSE 
222235_s_at 3.83E-10 up 13.31196 CSGALNACT2 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Complement 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
200983_x_at 1.18E-09 up 4.196889 CD59 
200984_s_at 1.67E-10 up 4.910066 CD59 
200985_s_at 3.02E-11 up 8.311746 CD59 
201925_s_at 3.14E-07 up 6.090309 CD55 
201926_s_at 4.95E-09 up 4.097339 CD55 
202953_at 5.10E-04 up 2.016919 C1QB 
205786_s_at 9.34E-11 up 3.896006 ITGAM 
206244_at 5.96E-11 up 7.560091 CR1 
209906_at 5.21E-09 up 5.687038 C3AR1 
210184_at 2.03E-05 up 2.185833 ITGAX 
212463_at 3.67E-08 up 3.248518 CD59 
217552_x_at 1.83E-09 up 3.938783 CR1 
218232_at 2.16E-05 up 3.030927 C1QA 
218983_at 2.04E-07 up 3.029844 C1RL 
220088_at 2.45E-06 up 2.500003 C5AR1 
205033_s_at 7.03E-06 up 6.365769 DEFA1/1B/3 
207269_at 1.49E-04 up 6.195451 DEFA4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Cathepsin 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
202450_s_at 4.73E-06 up 2.020977 CTSK 
203758_at 3.84E-07 down 2.476479 CTSO 
205653_at 4.28E-04 up 3.634934 CTSG 
210042_s_at 5.41E-05 up 2.824491 CTSZ 
214450_at 9.49E-04 down 2.150796 CTSW 
200661_at 1.10E-07 up 2.603046 CTSA 
200766_at 3.02E-11 up 3.793397 CTSD 
201487_at 2.22E-07 up 3.024736 CTSC 
203948_s_at 6.35E-04 up 2.112642 MPO 
203949_at 5.14E-06 up 4.61238 MPO 
204961_s_at 5.23E-06 up 2.092114 NCF1B1C 
207677_s_at 5.21E-09 up 3.07743 NCF4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table10. CSF 
    Probe Set ID Pvalue Arrow Fold Gene Symbol 
205159_at 7.47E-05 up 2.272558 CSF2RB 
210340_s_at 6.06E-10 up 2.727757 CSF2RA 
203591_s_at 4.27E-06 up 2.365631 CSF3R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. Fc receptor 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
203561_at 5.57E-08 up 2.06512 FCGR2A 
204232_at 6.41E-10 up 2.89912 FCER1G 
207674_at 4.21E-07 up 6.511793 FCAR 
210992_x_at 2.25E-05 up 2.003132 FCGR2C 
211307_s_at 3.73E-07 up 4.462972 FCAR 
211734_s_at 7.11E-05 down 4.276542 FCER1A 
211816_x_at 2.46E-05 up 2.47651 FCAR 
214511_x_at 1.06E-05 up 3.171251 FCGR1B 
216950_s_at 4.67E-08 up 5.148257 FCGR1A/1C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12. Cytokine & receptor 
  Probe Set ID Pvalue Arrow Fold Gene Symbol 
203828_s_at 6.11E-04 down 2.216758 IL32 
205227_at 4.73E-04 up 2.365252 IL1RAP 
205291_at 2.41E-06 down 3.160494 IL2RB 
205403_at 5.96E-11 up 9.990063 IL1R2 
205707_at 5.70E-06 down 2.016105 IL17RA 
205798_at 2.19E-21 down 28.62358 IL7R 
205926_at 2.78E-10 down 2.211585 IL27RA 
205945_at 9.53E-14 down 13.61186 IL6R 
205992_s_at 3.86E-06 up 3.345045 IL15 
206618_at 1.05E-11 up 17.52686 IL18R1 
207072_at 3.95E-11 up 6.322352 IL18RAP 
208200_at 3.63E-09 down 4.584162 IL1A 
208930_s_at 7.16E-10 down 4.59278 ILF3 
211372_s_at 2.35E-10 up 17.05508 IL1R2 
212195_at 9.18E-05 up 2.753398 IL6ST 
212196_at 1.44E-05 up 2.060642 IL6ST 
212657_s_at 3.37E-06 up 2.343125 IL1RN 
217489_s_at 9.59E-13 down 3.415206 IL6R 
202948_at 1.06E-10 up 9.925212 IL1R1 
203233_at 1.18E-09 up 3.541053 IL4R 
205016_at 6.86E-09 up 4.867131 TGFA 
201506_at 1.41E-04 down 2.289291 TGFBI 
203085_s_at 1.35E-05 up 2.13325 TGFB1 
204731_at 3.89E-15 down 10.80744 TGFBR3 
206026_s_at 7.23E-06 up 4.685213 TNFAIP6 
206222_at 3.55E-07 down 2.189329 TNFRSF10C 
207536_s_at 4.78E-06 down 2.923358 TNFRSF9 
207643_s_at 1.78E-08 up 2.618468 TNFRSF1A 
207907_at 3.57E-08 down 3.31319 TNFSF14 
208296_x_at 8.56E-05 up 2.646926 TNFAIP8 
210260_s_at 5.80E-05 up 2.88896 TNFAIP8 
214329_x_at 2.56E-04 up 2.679365 TNFSF10 
202509_s_at 8.86E-10 down 2.258532 TNFAIP2 
208114_s_at 6.33E-16 down 6.286403 ISG20L2 
208965_s_at 1.52E-08 down 6.302218 IFI16 
211676_s_at 1.42E-07 up 4.556334 IFNGR1 
220577_at 8.19E-07 down 2.331832 GVINP1 
201642_at 8.60E-08 up 2.225393 IFNGR2 
202269_x_at 1.73E-05 down 4.987527 GBP1 
202727_s_at 9.68E-08 up 3.452631 IFNGR1 
204191_at 2.33E-07 up 2.031339 IFNAR1 
204415_at 0.004538 up 2.774495 IFI6 
204439_at 0.004491 down 3.991523 IFI44L 
204747_at 5.65E-04 down 3.737294 IFIT3 
204786_s_at 5.62E-17 down 6.491528 IFNAR2 
200704_at 1.66E-07 up 2.056096 LITAF 
201108_s_at 3.76E-05 up 2.314963 THBS1 
201109_s_at 2.60E-05 up 3.128824 THBS1 
201110_s_at 1.47E-08 up 7.142229 THBS1 
204780_s_at 3.86E-04 up 2.720255 FAS 
204781_s_at 9.11E-05 up 2.032212 FAS 
221601_s_at 1.46E-09 down 4.684259 FAIM3 
221602_s_at 2.90E-10 down 3.944784 FAIM3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. CD molecules 
   Probe Set ID Pvalue Arrow Fold Gene Symbol 
200663_at 1.23E-10 up 2.64625 CD63 
201005_at 1.19E-06 up 4.053223 CD9 
202878_s_at 1.20E-04 up 2.316249 CD93 
202910_s_at 1.39E-04 up 2.078598 CD97 
203645_s_at 1.60E-06 up 7.818829 CD163 
203799_at 0.002884 up 2.038077 CD302 
204489_s_at 3.25E-10 up 2.475646 CD44 
204490_s_at 1.31E-08 up 2.582747 CD44 
204627_s_at 3.45E-05 up 3.667203 ITGB3 
204661_at 7.10E-06 down 2.483425 CD52 
205173_x_at 7.28E-08 up 4.151193 CD58 
205758_at 1.12E-04 down 3.211919 CD8A 
205789_at 4.22E-05 up 2.844588 CD1D 
205831_at 2.21E-07 down 4.421892 CD2 
205987_at 1.13E-07 down 2.078875 CD1C 
205988_at 1.13E-15 down 5.71907 CD84 
206150_at 2.30E-08 down 2.506513 CD27 
206488_s_at 6.10E-04 up 2.481129 CD36 
206493_at 5.05E-06 up 3.000028 ITGA2B 
206494_s_at 7.02E-04 up 3.137038 ITGA2B 
206761_at 3.30E-04 down 2.113857 CD96 
206804_at 6.16E-10 down 4.490583 CD3G 
208405_s_at 8.52E-05 up 2.330166 CD164 
208650_s_at 7.09E-07 up 6.548884 CD24 
208651_x_at 6.39E-08 up 4.732706 CD24 
208652_at 1.21E-07 up 2.66052 PPP2CA 
208653_s_at 6.26E-10 up 5.120652 CD164 
208654_s_at 3.97E-06 up 5.608513 CD164 
209555_s_at 2.95E-04 up 2.950439 CD36 
209771_x_at 1.32E-07 up 6.559978 CD24 
209835_x_at 1.06E-06 up 2.202673 CD44 
210031_at 1.34E-06 down 3.413696 CD247 
210184_at 2.03E-05 up 2.185833 ITGAX 
210895_s_at 2.39E-04 down 2.251445 CD86 
211744_s_at 5.92E-08 up 4.172478 CD58 
211893_x_at 8.92E-10 down 2.082775 CD6 
211900_x_at 5.14E-12 down 2.56049 CD6 
212014_x_at 7.54E-07 up 2.308336 CD44 
212063_at 4.06E-06 up 2.119029 CD44 
213958_at 1.17E-06 down 2.205519 CD6 
215049_x_at 2.45E-06 up 7.967604 CD163 
215240_at 1.19E-08 up 2.467146 ITGB3 
216233_at 4.99E-06 up 6.556412 CD163 
216331_at 0.001993 up 2.434621 ITGA7 
216379_x_at 5.86E-08 up 7.598393 CD24 
216942_s_at 1.49E-05 up 3.193467 CD58 
216956_s_at 1.65E-04 up 2.29709 ITGA2B 
217523_at 9.19E-10 down 6.259623 CD44 
219669_at 4.80E-13 up 52.83338 CD177 
222061_at 2.36E-09 up 3.870316 CD58 
266_s_at 6.15E-09 up 9.687818 CD24 
213539_at 1.57E-06 down 3.240318 CD3D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. NK/CTL molecules 
  Probe Set ID Pvalue Arrow Fold Gene Symbol 
205821_at 8.68E-07 down 3.717665 KLRK1 
206666_at 6.47E-06 down 3.898898 GZMK 
207460_at 5.21E-06 down 2.196101 GZMM 
207795_s_at 8.11E-05 down 2.646551 KLRD1 
210164_at 3.84E-06 down 4.671744 GZMB 
210288_at 2.27E-09 down 5.673069 KLRG1 
210321_at 2.14E-05 down 6.098404 GZMH 
210606_x_at 2.18E-05 down 2.995347 KLRD1 
210915_x_at 2.72E-06 down 3.166231 TRBC1 
210972_x_at 3.84E-07 down 3.223779 TRAC/J17/V20 
211796_s_at 2.86E-06 down 3.233982 TRBC1/C2 
211902_x_at 3.75E-06 down 2.651879 TRD@ 
213193_x_at 8.35E-07 down 3.394675 TRBC1 
213830_at 1.16E-08 down 3.694018 TRD@ 
214470_at 4.30E-04 down 2.832583 KLRB1 
214617_at 2.56E-04 down 3.489038 PRF1 
215338_s_at 2.44E-19 down 13.36511 NKTR 
215806_x_at 2.27E-05 down 3.907998 TARP/TRGC2 
216191_s_at 3.85E-06 down 5.215065 TRDV3 
216920_s_at 1.31E-06 down 5.017736 TARP/TRGC2 
217143_s_at 6.84E-08 down 6.090665 TRD@ 
220646_s_at 0.004097 down 2.571194 KLRF1 
37145_at 4.61E-06 down 5.027259 GNLY 
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